Timing note: The stated event date is Wednesday, July 29, 2026—which is today, not tomorrow. This preview is therefore framed for the report/call expected on July 29.
Fortive entered 2026 with a strong first quarter, but investors should focus less on whether it exceeds a narrowly framed quarterly number and more on whether management can demonstrate that the underlying growth, margin, and capital-allocation trajectory is sustaining after a favorable Q1 selling-day benefit.
In Q1, Fortive delivered 5.3% core revenue growth, 13% adjusted EBITDA growth, and 25% adjusted EPS growth. However, total company growth benefited by roughly 150 bps from additional selling days. The important 2Q test is whether growth remains near the high end of the company’s 2–3% full-year core-growth framework without that calendar assistance—and whether the strongest areas, notably Fluke, facility/asset-lifecycle software, gas detection, and healthcare software/consumables, continue to offset softer discretionary healthcare capital spending.
Management’s own setup was constructive: it expected Q2 and Q3 adjusted EPS to be broadly similar to Q1’s $0.70, core growth to trend toward the upper end of the annual range, and Q2 reported revenue to receive roughly a 150-bps combined FX and M&A tailwind.
Q1’s 5.3% core growth was strong, but the quality of that result differed by segment:
| 1Q26 metric | Intelligent Operating Solutions | Advanced Healthcare Solutions | Total Fortive |
|---|---|---|---|
| Revenue | $743M | $326M | $1.069B |
| Core growth | 5.2% | 5.8% | 5.3% |
| Q1 selling-day benefit | ~100 bps | ~300 bps | ~150 bps |
| Adjusted EBITDA margin | 34.3% | 25.7% | 29.3% |
IOS is the more important earnings-driver. It is roughly 70% of revenue and carries a mid-30s adjusted EBITDA margin. Investors will want confirmation that its underlying growth remains healthy, particularly in Fluke, facility and asset lifecycle (“FAL”) software, and Industrial Scientific gas detection.
AHS has the more difficult comparison in terms of quality of growth. Its Q1 calendar benefit was larger, while hospital capital-equipment purchasing remained cautious. The upside case is that continued strength in sterilization consumables, services, dosimetry, and procedure/documentation software more than offsets modest capital-market pressure.
Fluke is central to the Fortive growth case. In Q1, management cited:
The data-center opportunity extends beyond initial construction: Fortive sees Fluke participating in testing, power quality, battery testing, imaging, calibration, fiber testing, and ongoing operations/maintenance. The pivotal question is whether management can offer more concrete evidence of sustained demand, customer specification wins, product pull-through, or incremental growth contribution—not simply reiterate a long-term opportunity.
FAL was a bright spot in Q1, growing faster than IOS even after adjusting for selling days. Management specifically cited continued ServiceChannel strength, particularly in North America, alongside favorable ARR, gross-dollar-retention, and net-dollar-retention indicators.
That makes software a key qualitative differentiator in the print. Investors should look for:
Fortive’s deferred revenue increased to $472 million at the end of Q1, while remaining performance obligations were $840 million, largely tied to software, service, and support arrangements. These are useful indicators of the company’s increasingly recurring revenue base.
Management said low-temperature sterilization capital demand improved modestly in Q1, though U.S. hospital spending remained cautious. It also noted that the capital funnel was healthy and that comparisons should ease from Q2 onward, since hospital-budget pressure began to affect results in 2Q25.
A constructive Q2 outcome would include:
A disappointing outcome would be a reacceleration of hospital-capex pressure, which could call into question the second-half growth setup.
Fortive’s Q1 adjusted gross margin declined about 100 bps year over year to just above 63%, primarily due to tariffs. IOS adjusted gross margin declined roughly 150 bps, with tariffs and mix both weighing on the result.
The company’s message has been that tariffs are fully countermeasured at the bottom line through pricing, productivity, sourcing, and other actions—though the gross-margin pressure should persist into part of Q3 before fading as the company laps countermeasures.
For Q2, investors should focus on the relationship between:
Management’s medium-term framework calls for 50–100 bps of annual adjusted EBITDA-margin expansion. Q1’s 140-bps expansion was aided by growth, cost actions, FX, and calendar dynamics; maintaining a credible margin path as comparisons and selling days become less favorable is more important than matching that first-quarter pace.
Fortive reaffirmed full-year 2026 adjusted EPS guidance of $2.90–$3.00 in April and said results were trending toward the upper half of that range. It also guided to:
The practical read-through: a quarterly beat without an upward shift in the full-year outlook may receive a muted reaction, particularly after the stock rallied into the report. FTV closed at $64.11 on July 28, up about 7% from its April 30 close after Q1 results.
A move toward the high end—or above it—would likely require some combination of:
Capital allocation is a major component of the New Fortive equity case. The company repurchased approximately $500 million of shares in Q1—about 8.9 million shares—and had repurchased roughly $1.8 billion, or just over 10% of diluted shares, since the Ralliant separation in June 2025.
That buyback activity has materially supported adjusted EPS growth. At the same time, it has been funded partly with commercial paper: Fortive ended Q1 with $1.24 billion of commercial paper outstanding and reported gross debt/adjusted EBITDA of 2.8x. In May, the company issued $1.1 billion of senior notes: $600 million of 4.75% notes due 2031 and $500 million of 5.25% notes due 2036.
The Q2 call should clarify the intended use of the new debt proceeds and how management balances further repurchases, potential bolt-on M&A, and deleveraging. Management has emphasized a preference for disciplined, accretive bolt-ons, but buybacks remain the dominant visible use of capital.
Fortive has set a reasonably favorable bar for 2Q: adjusted EPS around the Q1 level, organic growth near the upper end of the full-year framework, and continued tariff offset at the bottom line. The report is likely to be judged on the durability and composition of growth rather than the headline EPS result alone.
The most constructive outcome would be a print showing resilient IOS demand, tangible Fluke/data-center traction, sustained software-led growth, incremental AHS recovery, and enough confidence to make an upper-half-of-guidance outcome feel conservative rather than merely achievable.